Current Clinical Applications of In Vivo Gene Therapy with AAVs

[1]  J. Cooper,et al.  Pathomechanisms in the neuronal ceroid lipofuscinoses. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[2]  S. Mole,et al.  Moving towards a new era of genomics in the neuronal ceroid lipofuscinoses. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[3]  Mingyao Li,et al.  Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology. , 2020, Human gene therapy.

[4]  J. Mendell,et al.  Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes , 2020, Pediatrics.

[5]  J. Mendell,et al.  Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy , 2020, JAMA neurology.

[6]  J. Rasko,et al.  Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  L. Chiriboga,et al.  Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice , 2020, Molecular therapy. Methods & clinical development.

[8]  Amy G. Feldman,et al.  Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type I. , 2020, The Journal of pediatrics.

[9]  A. Cideciyan,et al.  Dose Range Finding Studies with Two RPGR Transgenes in a Canine Model of X-linked Retinitis Pigmentosa Treated with Subretinal Gene Therapy. , 2020, Human Gene Therapy.

[10]  B. Lujan,et al.  Intraoperative optical coherence tomographic findings in patients undergoing subretinal gene therapy surgery , 2020, International Journal of Retina and Vitreous.

[11]  V. Sothilingam,et al.  Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia , 2020, JAMA ophthalmology.

[12]  S. Boye,et al.  Novel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene Therapy. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  S. Gray,et al.  Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies , 2020, Brain Research.

[14]  Cécile Fortuny,et al.  In vivo directed evolution of AAV in the primate retina. , 2020, JCI insight.

[15]  T. Ciulla,et al.  Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases , 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[16]  M. Siirin,et al.  Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum. , 2020, Blood.

[17]  R. Samulski,et al.  Engineering adeno-associated virus vectors for gene therapy , 2020, Nature Reviews Genetics.

[18]  J. Mendell,et al.  Clinical development on the frontier: gene therapy for duchenne muscular dystrophy , 2020, Expert opinion on biological therapy.

[19]  G. Noronha,et al.  Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates , 2020, Molecular therapy. Methods & clinical development.

[20]  M. Laffan,et al.  Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. , 2020 .

[21]  A. Cideciyan,et al.  Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives , 2019, Progress in Retinal and Eye Research.

[22]  D. Warnock,et al.  Current and Investigational Therapeutics for Fabry Disease , 2019, Kidney international reports.

[23]  E. Seifried,et al.  Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B , 2019, Blood.

[24]  John E. Murphy,et al.  Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year , 2019, Blood.

[25]  F. Bushman,et al.  Long-Term AAV-Mediated Factor VIII Expression in Nine Hemophilia A Dogs: A 10 Year Follow-up Analysis on Durability, Safety and Vector Integration , 2019, Blood.

[26]  S. Pipe,et al.  First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A , 2019, Blood.

[27]  A. Leavitt,et al.  Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A , 2019, Blood.

[28]  Nikolas Pontikos,et al.  GUCY2D-Associated Leber Congenital Amaurosis: A Retrospective Natural History Study in Preparation for Trials of Novel Therapies , 2019, American journal of ophthalmology.

[29]  M. Fiscella,et al.  AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. , 2019, The Journal of clinical investigation.

[30]  L. Kremer,et al.  Giant axonal neuropathy: a multicenter retrospective study with genotypic spectrum expansion , 2019, neurogenetics.

[31]  B. Lam,et al.  Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration. , 2019, Retina.

[32]  P. Bosma,et al.  Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler–Najjar Syndrome , 2019, Human gene therapy.

[33]  Jeffrey S. Stonebraker,et al.  Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males , 2019, Annals of Internal Medicine.

[34]  Kathleen A. Marshall,et al.  Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. , 2019, Ophthalmology.

[35]  J. Mendell,et al.  Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. , 2019, Pediatric neurology.

[36]  B. Wilhelm,et al.  Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia: A Randomized Clinical Trial. , 2019, JAMA ophthalmology.

[37]  V. Arruda,et al.  Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. , 2019, JCI insight.

[38]  Tyler B. Johnson,et al.  Gene Therapy Corrects Brain and Behavioral Pathologies in CLN6-Batten Disease , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  M. Ragni,et al.  The national blueprint for future factor VIII inhibitor clinical trials: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  H. Petry,et al.  Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs , 2019, Molecular therapy. Methods & clinical development.

[41]  J. Sahel,et al.  Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1/2 Clinical Trial , 2019, JAMA ophthalmology.

[42]  Alastair J. Martin,et al.  Magnetic resonance imaging–guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease , 2019, Annals of neurology.

[43]  L. Servais,et al.  X-linked myotubular myopathy , 2019, Neurology.

[44]  M. Ragni,et al.  Incidence and risk factors for hepatocellular cancer in individuals with haemophilia: A National Inpatient Sample Study , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[45]  Takeshi Nakajima,et al.  Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency , 2019, Brain : a journal of neurology.

[46]  P. Reitsma,et al.  High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor , 2018, Journal of thrombosis and haemostasis : JTH.

[47]  V. Arruda,et al.  Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy , 2018, Molecular therapy. Methods & clinical development.

[48]  J. Mendell,et al.  Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapy , 2018, Pediatric pulmonology.

[49]  W. Hauswirth,et al.  Six Years and Counting: Restoration of Photopic Retinal Function and Visual Behavior Following Gene Augmentation Therapy in a Sheep Model of CNGA3 Achromatopsia. , 2018, Human gene therapy.

[50]  M. Carr,et al.  Activity of a FIX-Padua Transgene Product in Commonly Used FIX:C One-Stage and Chromogenic Assay Systems Following PF-06838435 (SPK-9001) Gene Delivery , 2018, Blood.

[51]  C. Morton,et al.  GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant , 2018, Blood.

[52]  A. Nienhuis,et al.  Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer , 2018, Blood.

[53]  V. Dhawan,et al.  Gene therapy reduces Parkinson’s disease symptoms by reorganizing functional brain connectivity , 2018, Science Translational Medicine.

[54]  T. Ohashi.  Gene therapy for lysosomal storage diseases and peroxisomal diseases , 2018, Journal of Human Genetics.

[55]  B. Davidson,et al.  Lysosomal storage diseases , 2018, Nature Reviews Disease Primers.

[56]  P. Sieving,et al.  Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  W. Hauswirth,et al.  Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector , 2018, Proceedings of the National Academy of Sciences.

[58]  R. Thangavel,et al.  Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet? , 2018, Journal of Alzheimer's disease : JAD.

[59]  D. Duan.  Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  M. Tuszynski,et al.  Adeno-Associated Viral Vector (Serotype 2)–Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial , 2018, JAMA neurology.

[61]  J. Mendell,et al.  Eteplirsen treatment for Duchenne muscular dystrophy , 2018, Neurology.

[62]  D. Rizopoulos,et al.  Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy , 2018, Journal of Inherited Metabolic Disease.

[63]  E. Seifried,et al.  Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. , 2018, Blood.

[64]  D. N. Adam,et al.  A Review of Fabry Disease. , 2018, Skin therapy letter.

[65]  J. Sahel,et al.  Safety of rAAV2/2-ND4 Gene Therapy for Leber Hereditary Optic Neuropathy. , 2018, Ophthalmology.

[66]  R. Valabrègue,et al.  Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  B. Byrne,et al.  A multicenter, retrospective medical record review of X‐linked myotubular myopathy: The recensus study , 2017, Muscle & nerve.

[68]  D. Perry,et al.  AAV5–Factor VIII Gene Transfer in Severe Hemophilia A , 2017, The New England journal of medicine.

[69]  L. George,et al.  Hemophilia gene therapy comes of age. , 2017, Hematology. American Society of Hematology. Education Program.

[70]  J. Rasko,et al.  Hemophilia B Gene Therapy with a High‐Specific‐Activity Factor IX Variant , 2017, The New England journal of medicine.

[71]  B. Byrne,et al.  Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. , 2017, The Lancet. Child & adolescent health.

[72]  J. ByrneBarry,et al.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease , 2017 .

[73]  C. Rae,et al.  Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy , 2017, Acta Neuropathologica.

[74]  W. Hauswirth,et al.  Gene Therapy for Leber Hereditary Optic Neuropathy: Low- and Medium-Dose Visual Results. , 2017, Ophthalmology.

[75]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[76]  R. Crystal,et al.  Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial , 2017, The Lancet Neurology.

[77]  Kathleen A. Marshall,et al.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.

[78]  K. Xue,et al.  Technique of retinal gene therapy: delivery of viral vector into the subretinal space , 2017, Eye.

[79]  Hanns Lochmüller,et al.  Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review , 2017, Orphanet Journal of Rare Diseases.

[80]  P. Campochiaro,et al.  Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial , 2017, The Lancet.

[81]  R. Grange,et al.  Long‐term effects of systemic gene therapy in a canine model of myotubular myopathy , 2017, Muscle & nerve.

[82]  A. Schambach,et al.  Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease , 2017, Molecular therapy. Methods & clinical development.

[83]  Ian J Constable,et al.  Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial. , 2017, American journal of ophthalmology.

[84]  J. Gill,et al.  Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. , 2017, Blood.

[85]  E. Eskandar,et al.  Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease. , 2017, JCI insight.

[86]  R. Grange,et al.  Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[87]  K. Lim,et al.  Eteplirsen in the treatment of Duchenne muscular dystrophy , 2017, Drug design, development and therapy.

[88]  T. Aleman,et al.  Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina. , 2017, Human gene therapy.

[89]  I. Constable,et al.  Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration , 2016, EBioMedicine.

[90]  R. Herzog,et al.  Potential for cellular stress response to hepatic factor VIII expression from AAV vector , 2016, Molecular therapy. Methods & clinical development.

[91]  D. Sabatino,et al.  Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice , 2016, Molecular therapy. Methods & clinical development.

[92]  M. Schuurmans,et al.  Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study , 2016, British journal of haematology.

[93]  P. Gimotty,et al.  A rapid pro-hemostatic approach to overcome direct oral anticoagulants , 2016, Nature Medicine.

[94]  Flora Peyvandi,et al.  The past and future of haemophilia: diagnosis, treatments, and its complications , 2016, The Lancet.

[95]  A. Moorman,et al.  Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[96]  B. Riske,et al.  Men with severe hemophilia in the United States: birth cohort analysis of a large national database. , 2016, Blood.

[97]  James M. Wilson,et al.  AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees. , 2016, Human gene therapy. Clinical development.

[98]  M. Makris,et al.  Factor VIII assay variability in postinfusion samples containing full length and B‐domain deleted FVIII , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[99]  W. Hauswirth,et al.  Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia. , 2016, Human gene therapy. Clinical development.

[100]  W. Feuer,et al.  Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results. , 2016, Ophthalmology.

[101]  B. Byrne,et al.  Targeted approaches to induce immune tolerance for Pompe disease therapy , 2016, Molecular therapy. Methods & clinical development.

[102]  Lili Wang,et al.  Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[103]  P. Gregory,et al.  Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery , 2015, Nucleic acids research.

[104]  W. Hauswirth,et al.  Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease , 2015, Proceedings of the National Academy of Sciences.

[105]  Kellie Howard,et al.  Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin. , 2015, Human gene therapy. Clinical development.

[106]  Jessica Zucman-Rossi,et al.  Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas , 2015, Nature Genetics.

[107]  B. Byrne,et al.  Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease , 2015, Annals of neurology.

[108]  B. Byrne,et al.  Altered activation of the tibialis anterior in individuals with Pompe disease: Implications for motor unit dysfunction , 2015, Muscle & nerve.

[109]  S. E. Barker,et al.  Long-term effect of gene therapy on Leber's congenital amaurosis. , 2015, The New England journal of medicine.

[110]  D. Armao,et al.  Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy , 2015, Molecular therapy. Methods & clinical development.

[111]  A. Schambach,et al.  Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[112]  E. Neufeld,et al.  Transition considerations for extended half‐life factor products , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[113]  V. Arruda,et al.  AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. , 2015, Blood.

[114]  L. Naldini,et al.  Liver-directed lentiviral gene therapy in a dog model of hemophilia B , 2015, Science Translational Medicine.

[115]  A. Elkahloun,et al.  Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. , 2015, The Journal of clinical investigation.

[116]  J. Bennett,et al.  The Status of RPE65 Gene Therapy Trials: Safety and Efficacy. , 2015, Cold Spring Harbor perspectives in medicine.

[117]  A. Ballabio,et al.  Lysosomal storage diseases: from pathophysiology to therapy. , 2015, Annual review of medicine.

[118]  J. Flannery,et al.  Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates , 2014, Gene Therapy.

[119]  Michael Recht,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[120]  A. Nienhuis,et al.  Our journey to successful gene therapy for hemophilia B. , 2014, Human gene therapy.

[121]  J. Mendell,et al.  Gene therapy for muscular dystrophy: moving the field forward. , 2014, Pediatric neurology.

[122]  M. Prausnitz,et al.  Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles. , 2014, Investigative ophthalmology & visual science.

[123]  A. Fleisher,et al.  A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[124]  W. Chung,et al.  Observational study of spinal muscular atrophy type I and implications for clinical trials , 2014, Neurology.

[125]  T. Conlon,et al.  B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study , 2014, Molecular therapy. Methods & clinical development.

[126]  D. Ginsburg,et al.  Murine coagulation factor VIII is synthesized in endothelial cells. , 2014, Blood.

[127]  Aaron D. Black,et al.  Adeno‐associated virus 8‐mediated gene therapy for choroideremia: preclinical studies in in vitro and in vivo models , 2014, The journal of gene medicine.

[128]  Cécile Fortuny,et al.  Retinoschisin gene therapy in photoreceptors, Müller glia, or all retinal cells in the Rs1h−/− mouse , 2014, Gene Therapy.

[129]  F. Cremers,et al.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial , 2014, The Lancet.

[130]  W. Hauswirth,et al.  Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A. , 2014, Human gene therapy methods.

[131]  R. Grange,et al.  Gene Therapy Prolongs Survival and Restores Function in Murine and Canine Models of Myotubular Myopathy , 2014, Science Translational Medicine.

[132]  K. Peerlinck,et al.  Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII , 2014, Journal of thrombosis and haemostasis : JTH.

[133]  R. Polishchuk,et al.  Effective delivery of large genes to the retina by dual AAV vectors , 2013, EMBO molecular medicine.

[134]  K. Cornetta,et al.  Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A , 2013, Nature Communications.

[135]  J. Mink,et al.  NCL diseases - clinical perspectives. , 2013, Biochimica et biophysica acta.

[136]  J. Mendell,et al.  Eteplirsen for the treatment of Duchenne muscular dystrophy , 2013, Annals of neurology.

[137]  A. Iorio,et al.  Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression , 2013, Journal of thrombosis and haemostasis : JTH.

[138]  James M. Wilson,et al.  CpG-depleted adeno-associated virus vectors evade immune detection. , 2013, The Journal of clinical investigation.

[139]  Deniz Dalkara,et al.  In Vivo–Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous , 2013, Science Translational Medicine.

[140]  N. Messaddeq,et al.  Site-specific Mtm1 mutagenesis by an AAV-Cre vector reveals that myotubularin is essential in adult muscle. , 2013, Human molecular genetics.

[141]  W. Hauswirth,et al.  Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors , 2013, PloS one.

[142]  P. Fagone,et al.  Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. , 2013, Blood.

[143]  T. Conlon,et al.  Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. , 2013, Human gene therapy.

[144]  R. Ljung,et al.  Factor VIII products and inhibitor development in severe hemophilia A. , 2013, The New England journal of medicine.

[145]  D. Shera,et al.  Long-Term Follow-Up After Gene Therapy for Canavan Disease , 2012, Science Translational Medicine.

[146]  R. Samulski,et al.  Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates , 2012, Gene Therapy.

[147]  P. Della Valle,et al.  Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. , 2012, Blood.

[148]  T. Nichols,et al.  The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. , 2012, Blood.

[149]  R. Richardson,et al.  Gene therapy for aromatic L-amino acid decarboxylase deficiency. , 2012, Neurosurgery.

[150]  B. Byrne,et al.  Gene Therapy for Aromatic l-Amino Acid Decarboxylase Deficiency , 2012, Science Translational Medicine.

[151]  C. Dunbar,et al.  Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[152]  K. Foust,et al.  Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. , 2012, Human gene therapy.

[153]  Cindy Hamil,et al.  Evidence‐based path to newborn screening for duchenne muscular dystrophy , 2012, Annals of neurology.

[154]  P. Pivirotto,et al.  Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. , 2012, Human gene therapy.

[155]  William J Feuer,et al.  Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. , 2012, Archives of ophthalmology.

[156]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[157]  N. Nagan,et al.  Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens , 2011, European Journal of Human Genetics.

[158]  M. Berger,et al.  T2 Imaging in Monitoring of Intraparenchymal Real-Time Convection-Enhanced Delivery , 2011, Neurosurgery.

[159]  R. Liesner,et al.  Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. , 2011, Blood.

[160]  S. Ojeda,et al.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[161]  Livia S. Carvalho,et al.  Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy , 2011, Human molecular genetics.

[162]  A. Nienhuis,et al.  Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[163]  David R Williams,et al.  Intravitreal injection of AAV2 transduces macaque inner retina. , 2011, Investigative ophthalmology & visual science.

[164]  T. Conlon,et al.  Pompe disease gene therapy. , 2011, Human molecular genetics.

[165]  A. Rezai,et al.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial , 2011, The Lancet Neurology.

[166]  D. Duan,et al.  Evidence for impaired neurovascular transmission in a murine model of Duchenne muscular dystrophy. , 2011, Journal of applied physiology.

[167]  N. Chatauret,et al.  Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. , 2011, Human molecular genetics.

[168]  G. Veres,et al.  Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[169]  F. Rosendaal,et al.  Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[170]  H. Kazazian,et al.  Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. , 2010, Blood.

[171]  R. Kaufman,et al.  In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. , 2010, Blood.

[172]  Artur V. Cideciyan,et al.  Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy , 2010, Progress in Retinal and Eye Research.

[173]  N. Tanimoto,et al.  Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[174]  P. Pivirotto,et al.  Real-time MR Imaging With Gadoteridol Predicts Distribution of Transgenes After Convection-enhanced Delivery of AAV2 Vectors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[175]  András M Komáromy,et al.  Gene therapy rescues cone function in congenital achromatopsia. , 2010, Human molecular genetics.

[176]  M. Rich,et al.  Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN , 2010, Nature Biotechnology.

[177]  V. Arruda,et al.  X-linked thrombophilia with a mutant factor IX (factor IX Padua). , 2009, The New England journal of medicine.

[178]  W. Jagust,et al.  Safety and tolerability of putaminal AADC gene therapy for Parkinson disease , 2009, Neurology.

[179]  A. Buj-Bello,et al.  T-tubule disorganization and defective excitation-contraction coupling in muscle fibers lacking myotubularin lipid phosphatase , 2009, Proceedings of the National Academy of Sciences.

[180]  C. Beattie,et al.  Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? , 2009, Nature Reviews Neuroscience.

[181]  P. Mannucci,et al.  Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[182]  J. Fyfe,et al.  Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[183]  M. Ragni,et al.  Extrahepatic factor VIII production in transplant recipient of hemophilia donor liver. , 2009, Blood.

[184]  R. Herzog,et al.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. , 2009, Blood.

[185]  W. Hauswirth,et al.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. , 2008, Human gene therapy.

[186]  Edwin M Stone,et al.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics , 2008, Proceedings of the National Academy of Sciences.

[187]  W. Hauswirth,et al.  Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential , 2008, Molecular vision.

[188]  M. Souweidane,et al.  Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. , 2008, Human gene therapy.

[189]  Nick Tyler,et al.  Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[190]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[191]  J. L. Eberling,et al.  Results from a phase I safety trial of hAADC gene therapy for Parkinson disease , 2008, Neurology.

[192]  A. Buj-Bello,et al.  AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis , 2008, Human molecular genetics.

[193]  P. Novikoff,et al.  Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. , 2008, The Journal of clinical investigation.

[194]  J. F. Wright,et al.  Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. , 2007, Blood.

[195]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[196]  Edward N Pugh,et al.  The Proteome of the Mouse Photoreceptor Sensory Cilium Complex*S , 2007, Molecular & Cellular Proteomics.

[197]  David Eidelberg,et al.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.

[198]  Marcela V Maus,et al.  CD8+ T-cell responses to adeno-associated virus capsid in humans , 2007, Nature Medicine.

[199]  J. D. Cameron,et al.  Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. , 2006, American journal of ophthalmology.

[200]  V. Planelles,et al.  Efficiency of lentiviral transduction during development in normal and rd mice. , 2006, Molecular vision.

[201]  J. Gorski,et al.  Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. , 2006, The Journal of clinical investigation.

[202]  H. El‐Serag,et al.  The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? , 2003, American Journal of Gastroenterology.

[203]  Theresa A. Storm,et al.  AAV serotype 2 vectors preferentially integrate into active genes in mice , 2003, Nature Genetics.

[204]  Hala G. Zahreddine,et al.  The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[205]  D. Shera,et al.  Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. , 2002, Human gene therapy.

[206]  B. Byrne,et al.  Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). , 2002, Current molecular medicine.

[207]  T. Wienker,et al.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. , 2002, American journal of human genetics.

[208]  J. Streilein,et al.  ANTERIOR CHAMBER ASSOCIATED IMMUNE DEVIATION (ACAID): REGULATION, BIOLOGICAL RELEVANCE, AND IMPLICATIONS FOR THERAPY , 2002, International reviews of immunology.

[209]  J. Kaldor,et al.  Estimating progression to cirrhosis in chronic hepatitis C virus infection , 2001, Hepatology.

[210]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.

[211]  M Stain,et al.  High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. , 2000, The New England journal of medicine.

[212]  R. Kaul,et al.  Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease , 2000, Annals of neurology.

[213]  J. McPherson,et al.  A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. , 1999, Human molecular genetics.

[214]  C. Lorson,et al.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[215]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[216]  R. Schiffmann,et al.  Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. , 1998, Human gene therapy.

[217]  B. Davidson,et al.  Gene therapy for lysosomal storage diseases. , 1998, Molecular therapy : the journal of the American Society of Gene Therapy.

[218]  S. Klauck,et al.  A gene mutated in X–linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast , 1996, Nature Genetics.

[219]  C. Dunbar,et al.  Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A phase I study. , 1996, Human gene therapy.

[220]  J. Spira,et al.  Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. , 1995, European journal of biochemistry.

[221]  K. Campbell.  Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage , 1995, Cell.

[222]  J. Vandenbroucke,et al.  Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis , 1995, The Lancet.

[223]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[224]  R. Kaufman,et al.  Role of the B domain for factor VIII and factor V expression and function. , 1994, Blood.

[225]  S. Arkin,et al.  Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A: Safety, Efficacy, and Development of Inhibitors , 1993 .

[226]  A. Giles,et al.  Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. , 1993, Blood.

[227]  S. Arkin,et al.  Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. , 1993, The New England journal of medicine.

[228]  D. Price,et al.  Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[229]  S. Karlsson,et al.  Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[230]  K. Davies,et al.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin , 1990, Nature.

[231]  F. Gage,et al.  Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor , 1987, Nature.

[232]  M. Koenig,et al.  Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.

[233]  K. Kurachi,et al.  Isolation and characterization of a cDNA coding for human factor IX. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[234]  Cécile Fortuny,et al.  In vivo–directed evolution of adeno-associated virus in the primate retina , 2020 .

[235]  J. Mendell,et al.  AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. , 2019, Journal of neuromuscular diseases.

[236]  Y. Chien,et al.  Natural History of Aromatic L-Amino Acid Decarboxylase Deficiency in Taiwan. , 2018, JIMD reports.

[237]  B. Wilhelm,et al.  CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA. , 2018, Retina.

[238]  Teresa H Y Wu,et al.  Lysosomal storage disorders. , 2018, Nature reviews. Disease primers.

[239]  N. Dejneka,et al.  A Subretinal Cell Delivery Method via Suprachoroidal Access in Minipigs: Safety and Surgical Outcomes. , 2018, Investigative ophthalmology & visual science.

[240]  T. Conlon,et al.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease. , 2017, Human gene therapy. Clinical development.

[241]  J. Stypmann,et al.  Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[242]  James M. Wilson,et al.  AAV natural infection induces broad cross-neutralizing antibody responses to multiple AAV serotypes in chimpanzees. , 2016, Human gene therapy. Clinical development.

[243]  P. Charbel Issa,et al.  Vesicular stomatitis virus glycoprotein- and Venezuelan equine encephalitis virus-derived glycoprotein-pseudotyped lentivirus vectors differentially transduce corneal endothelium, trabecular meshwork, and human photoreceptors. , 2014, Human gene therapy.

[244]  G. Stern.  Niemann-Pick's and Gaucher's diseases. , 2014, Parkinsonism & related disorders.

[245]  A. Ballabio,et al.  Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. , 2014, Human gene therapy.

[246]  T. Conlon,et al.  Phase I / II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase ( rAAV 1-CMV-GAA ) Gene Vector in Patients with Pompe Disease , 2014 .

[247]  A. J. Roman,et al.  Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. , 2013, Human molecular genetics.

[248]  J. Stockman.  Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom , 2013 .

[249]  K. Nicholls,et al.  Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy. , 2012, JIMD reports.

[250]  Mark R. Prausnitz,et al.  Suprachoroidal Drug Delivery to the Back of the Eye Using Hollow Microneedles , 2010, Pharmaceutical Research.

[251]  Xiaomin Su,et al.  Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[252]  H. Mizukami,et al.  A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[253]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[254]  J. Niederkorn.  Immune privilege in the anterior chamber of the eye. , 2002, Critical reviews in immunology.

[255]  A. Almstedt,et al.  Structural and Functional Characteristics of the B-domain-deleted Recombinant Factor VIII Protein, r-VIII SQ , 2001, Thrombosis and Haemostasis.

[256]  M. Brooke,et al.  The natural history of Duchenne muscular dystrophy: a caveat for therapeutic trials. , 1981, Transactions of the American Neurological Association.